Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Timothy A. Yap et al.|Clinical Cancer Research|2011Cited by 168
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaAndrew Spencer, Christine Chen, Sung‐Soo Yoon et al.|Blood|2014Cited by 140
Dose-Finding Quantitative <sup>18</sup>F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Güngör, Hani Gabra, Azeem Saleem et al.|Journal of Nuclear Medicine|2015Cited by 27
Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumorsDavid Olmos, Sarah P. Blagden, Alicia J. Allred et al.|Journal of Clinical Oncology|2009Cited by 22
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.Hatice Güngör, Hani Gabra, Azeem Saleem et al.|Journal of Clinical Oncology|2011Cited by 14